});

MEET OUR TEAM

We aspire to have a material impact on patient care, pushing forward the science that will make our company a powerhouse in the field of dermatology. To us, that means creating novel solutions that benefit individuals and society, bringing new scientific understanding to diseases for which there are no adequate treatments.

Ian Tolfree, PhD
CEO & Founder

Ian has extensive startup experience acquired from both running his own and building Johns Hopkins accelerator program, where he worked with over 70 in a variety of capacities startups ranging from therapeutics and devices to new materials and imaging techniques.  His support included, among other things,  development and business planning, designing and overseeing large animal trials, customer outreach and executive coaching. Dr. Tolfree received a B.S. in Applied Physics from Columbia University in the City of New York, and his Ph.D. in Theoretical Physics from Johns Hopkins University. 

Business Advisors

Joseph Stewart
Managing Director,
Mizuho

Joe Stewart joined Mizuho to build out an institutional derivatives platform after a long career at UBS.  Platform fund raising via complex investment themes across asset classes has been a special focus - originating financing and access to capital markets – where Joe has serviced clients of the bank in specialized solutions for over two decades.

Bruce Wang, PhD
CEO, Elysia Group

Elysia Group, LLC, a Health Economics and Outcomes Research consultancy, which Bruce co-founded in 2014. He worked with over 20 biotech and pharmaceutical companies to provide market access and health economic solutions in the United States, Asia, and emerging markets. His experience spans dozens of therapeutic areas and indications across products generating billions of dollars annually.

Michael Richman,
CEO,
NextCure

Mike is the CEO of NextCure, an immunooncology immuno-oncology company he took from startup to IPO.  Previously, Mr. Richman served as the President and CEO of Amplimmune, which was acquired by AstraZeneca for $500M in 2013.

Clinical Advisors

Howard Maibach, MD
Professor, UCSF

Dr. Maibach is one of the best known topical dermatologists of all time, having been a pioneer in the field since it's inception.  He has been instrumental in the development and approval of a number of blockbuster products.

Tom Mustoe, MD

Tom Mustoe, MD, was Chief of Plastic Surgery at Northwestern University Hospital for almost 20 years, and inventor of our scarring portfolio.  He is a leader in the underlying biology behind scarring.  Dr. Mustoe has earned a worldwide reputation for his technical skill as well as his refined aesthetic sensibility.

Hari
Nadaminti, MD, MBA
Chair of Dermatology, Summit Medical Group

Hari Nadiminti, MD, MBA is the Chairman of Dermatology at the Summit Medical Group, the largest multispecialty group in New Jersey.  He was trained at Massachusetts General Hospital-Harvard University, New York Presbyterian Hospital - Weill Cornell, and Emory University.  He is the recipient of the many awards including Patients’ Choice Award and American Society of Dermatologic Surgery Young Investigators Writing Award. . 

Rebecca Baxt, MD, MBA, FAAD
CEO, Baxt Cosmedical

Board Certified Dermatologist and owner at Baxt Cosmedical - New Jersey’s and New York’s foremost center for advanced, innovative cosmetic services and procedures.